Novantrone (Mitoxantrone Hydrochloride)

Mitoxantrone intercalates into DNA, disrupting its structure, and blocks topoisomerase II activity. This prevents DNA unwinding and replication, leading to double‑strand breaks, cell‑cycle arrest, and apoptosis of malignant or activated immune cells.

The dose of Novantrone is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and prior treatment history. No standard dosing can be provided without a medical assessment.

Safety data for Mitoxantrone in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It is generally avoided in pregnant or nursing women because of potential fetal or infant toxicity.

To order Novantrone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Novantrone belongs to the anthracenedone class and differs from anthracyclines by its distinct DNA intercalation and topoisomerase II inhibition profile. While both have cytotoxic activity, Mitoxantrone typically shows less cumulative cardiotoxicity than doxorubicin but still requires cardiac monitoring, especially when combined with other cardiotoxic drugs.

Novantrone should be stored at 2‑8 °C in a refrigerator, protected from light. The product must not be frozen or shaken. Maintain the cold‑chain during transport and keep the vial in its original packaging until use.

Novantrone is given by intravenous infusion. The preparation is reconstituted according to the manufacturer’s instructions and administered over a period defined by the treating physician, typically ranging from 30 minutes to several hours, depending on the clinical protocol.

Serious adverse events include cardiotoxicity leading to reduced left‑ventricular function, secondary acute leukemia, severe infections due to profound myelosuppression, and hepatic toxicity. Patients should be monitored closely for signs of heart failure, new malignancies, infection, and liver enzyme elevations.

Novantrone is contraindicated in patients with known hypersensitivity to Mitoxantrone or any formulation component, those with uncontrolled active infections, and individuals with severe pre‑existing cardiac disease. Caution is also advised for patients with significant hepatic or renal impairment.